Drug class profile · refreshed daily from federal data

Cholinergic Muscarinic Agonist

2 molecules in this class, $15.9M combined CY2024 Part D spend across 291K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Cholinergic Muscarinic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $15.9Mcombined across class
Total Rx claims: 291K78K unique beneficiaries
Generic mfrs (active): 4across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Bethanechol

291K Part D claims (CY24) · 78K beneficiaries · First FDA approval: 2007-10-26

4 generic mfrs 0 plans require PA

Low NADAC$0.111

→

Avg plan cost$0.184

Part D spend $15.9M 2× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Xanomeline and Trospium

Brand: Cobenfy · — Part D claims (CY24) · First FDA approval: 2024-09-27

Brand-only (no generics) 928 plans require PA

Low NADAC$30.15

→

Avg plan cost$30.25

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.